[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351827-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351827-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","omacetaxine-reduces-c-myc-expression-and-demonstrates-antitumor-effects-in-osteosarcoma","Omacetaxine reduces c-Myc expression and demonstrates antitumor effects in osteosarcoma","","Omacetaxine mepesuccinate (OMX), a protein translation inhibitor, is investigated as a potential therapy for osteosarcoma across canine, human, and mouse models. Using osteosarcoma cell lines, the study evaluates growth inhibition, migration and invasion, apoptosis, c-Myc expression, and downstream gene-expression changes. OMX produces dose-dependent growth suppression and apoptosis in the low-nanomolar IC50 range, reduces migration and Matrigel invasion, and lowers c-Myc protein and Myc target transcripts. In orthotopic mouse models, OMX significantly inhibits tumor growth and metastasis, supporting further clinical development for c-Myc-driven cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/omacetaxine-reduces-c-myc-expression-and-demonstrates-antitumor-effects-in-osteosarcoma/351827/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/omacetaxine-reduces-c-myc-expression-and-demonstrates-antitumor-effects-in-osteosarcoma/351827.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is omacetaxine (OMX) and how does it work in this study?","Question",{"text":63,"@type":64},"OMX is a protein translation inhibitor. It blocks translation to reduce new c-Myc protein production, which can lead to antitumor effects in osteosarcoma cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did OMX affect osteosarcoma cells in vitro?",{"text":68,"@type":64},"OMX caused dose-dependent growth inhibition and apoptosis, with IC50 values in the low nanomolar range. It also reduced migration and Matrigel invasion.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports OMX efficacy in vivo?",{"text":72,"@type":64},"OMX significantly inhibited tumor growth and metastasis in two separate orthotopic mouse osteosarcoma models, with associated reductions in c-Myc-related expression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351827,1790180494,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nOmacetaxine reduces c-Myc expression and demonstrates antitumor effects in osteosarcoma  \nKristen B. Farrell􀀍, Sunetra Das & Douglas H. Thamm  \nOmacetaxine mepesuccinate (OMX), formerly known as homoharringtonine, is a protein translation inhibitor approved for use in human chronic myeloid leukemia. Recent studies suggest that OMX may be effective against other cancer types, and may be successful against protein targets that are otherwise difficult to inhibit by reducing their translation rates. Using canine, human, and mouse osteosarcoma (OS) cell lines, we investigated the antineoplastic effects of OMX against OS by evaluating growth inhibition, migration and invasion, apoptosis, expression of c-Myc, changes in gene expression, and in vivo efficacy. OMX induced dose-dependent growth inhibition and apoptosis of OS cells with IC50 values in the low nanomolar range. OMX also reduced migration and Matrigel invasion.  \nStrikingly, levels of c-Myc protein were reduced in most canine, human, and mouse OS cell lines after OMX exposure, and Myc target RNA transcripts were also reduced with treatment. OMX significantly inhibited tumor growth in and metastasis in two separate orthotopic mouse OS models. OMX is a promising candidate for treatment of OS in both dogs and humans, and potentially other c-Myc-driven cancers.  \nKeywords Osteosarcoma, Omacetaxine, c-Myc, Canine cancer, Protein translation  \nAbbreviations  \nDEG Differentially expressed gene GSEA Gene set enrichment analysis  \nOMX Omacetaxine OS Osteosarcoma  \nOsteosarcoma (OS) is the most common primary bone tumor in both humans and dogs. Treatments for OS have not advanced in three decades, resulting in a stagnation of survival expectations for both species1,2. Although OS is rare in humans with about 1,000 new cases per year in the United States, it is more common in canine patients, especially large breed dogs, with about 10–20,000 cases per year3,4. OS is pathologically indistinguishable between human and canine cases, and the disease progresses similarly in both species, although with a compressed timeline in dogs. The spontaneous development of the disease, similar pathology, an accelerated disease progression associated with the comparatively shorter canine lifespan, and increased case numbers, all make canine OS an attractive model for OS research5–10.  \nOmacetaxine mepesuccinate (OMX), also known as homoharringtonine, or brand name Synribo™ (Teva Pharmaceuticals), is an FDA approved treatment for human chronic myeloid leukemia with tyrosine kinase inhibitor resistance11, 12. OMX is a protein translation inhibitor that functions by blocking the A site of the ribosome to prevent amino acid chain elongation13. Although clinical studies using OMX are limited to hematological malignancies12, 14, some preclinical research has shown promising function in other tumor types. Multiple studies demonstrate the effects of OMX on various cell signaling pathways and induction of apoptosis in several solid tumor types14.  \nc-Myc is a transcription factor regulating multiple essential processes such as cell division and apoptosis, and is constitutively or over-expressed in the majority of cancers, including OS15. c-Myc is difficult to directly inhibit due to its largely disordered structure lacking binding pockets for small molecule inhibitors, along with principally nuclear localization of the protein16. However, reduction of c-Myc levels has been observed after OMX treatment in hematological malignancies17, 18, a phenomenon that has also been demonstrated using other methods of translational inhibition19,20. C-Myc has a short cellular half-life of approximately 25 min21,22; thus, blocking translation of new c-Myc results in degradation via proteolysis without replacing the protein  \nFlint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, 1620 Campus Delivery, Fort Collins, ","cbCainDlWw9PMVs7","https://ap.wps.com/l/cbCainDlWw9PMVs7","pdf",3034522,13,"English","# Materials and methods\n## Cell culture and growth inhibition assays","[{\"question\":\"What is omacetaxine (OMX) and how does it work in this study?\",\"answer\":\"OMX is a protein translation inhibitor. It blocks translation to reduce new c-Myc protein production, which can lead to antitumor effects in osteosarcoma cells.\"},{\"question\":\"How did OMX affect osteosarcoma cells in vitro?\",\"answer\":\"OMX caused dose-dependent growth inhibition and apoptosis, with IC50 values in the low nanomolar range. It also reduced migration and Matrigel invasion.\"},{\"question\":\"What evidence supports OMX efficacy in vivo?\",\"answer\":\"OMX significantly inhibited tumor growth and metastasis in two separate orthotopic mouse osteosarcoma models, with associated reductions in c-Myc-related expression.\"}]","Omacetaxine reduces c-Myc expression and demonstrates antitumor effects in osteosarcoma | PDF",1790096180,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dedd9e63099569e118dc3175ba2477c7.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f694b76d786046c1107fb34f2835772c.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2417152a862d7c7de058abc423f1459.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6ad7b2d41c75587799e0efa5f66ded3.webp",980,1287]